McKesson Q3: A Buy-the-News Setup or a Guidance Lift?

The immediate event is clear. McKesson delivered a solid quarterly beat and then raised its full-year outlook. For the third quarter ended December 31, 2025, the company posted adjusted diluted EPS of $9.34, up 16% on consolidated revenue of $106.2 billion, a rise of 11%. More importantly, management responded to this strong performance by lifting its guidance. The new full-year adjusted EPS range is now $38.80 to $39.20, up from the previous $38.35 to $38.85. This implies 17% to 19% growth for the year, a notable step-up.

This guidance lift is the key catalyst. It transforms a good quarterly report into a forward-looking upgrade. The company cited "operational execution and enhanced efficiency" as drivers, with a 138 basis point improvement in expenses as a percentage of gross profit noted as a positive. The strategic context adds a layer of clarity: the sale of its Norwegian businesses was completed on January 30, 2026, marking a clean exit from European operations. This divestiture, which contributed $0.05 to the quarter's EPS, removes a legacy business and focuses the company's capital and strategy on its core U.S. distribution platforms.

So, does this create a clear near-term trading opportunity? The setup is tactical. The beat and guidance raise are positive catalysts that typically drive a stock higher. However, the market may have already priced in strong execution. The real opportunity hinges on whether this guidance lift is a meaningful acceleration or simply a reaffirmation of the known momentum. The raised range is narrower, suggesting management has more confidence, but the underlying growth drivers-like GLP-1 distribution revenue reaching $14 billion, up 26% year-over-year-were already well-known. The event-driven play is to buy the news of the raised guide, but the risk is that the stock has already rallied on expectations.

The Tactical Setup: Drivers and the Next Milestone

The Q3 beat was broad-based, but the real story is in the segments. North American Pharmaceutical revenue climbed 9% to $88.3 billion, driven by prescription volume growth and specialty distribution strength. More importantly, the oncology and biopharma services platforms are where the explosive growth is happening. The Oncology and Multispecialty segment saw revenue surge 37% to $13 billion, with operating profit expanding a staggering 57%. This isn't just volume; it's a platform expansion fueled by acquisitions and a ramp in specialty product distribution.

The immediate next catalyst is now in the calendar. Management confirmed it has completed the transition service agreements for its Medical-Surgical Solutions business and is targeting an IPO in the second half of 2027. That timeline is critical. It creates a clear, near-term event that could move the stock. The separation is a multi-year process, but the IPO target date anchors the narrative. It shifts the focus from current profitability to future valuation potential for that unit, which management has noted can introduce quarterly variability.

For now, the stock's momentum is tied to execution on the core. The raised guidance suggests management sees this oncology and specialty distribution growth as sustainable. The key question for the next trading session is whether the market views the IPO timeline as a positive catalyst that justifies a higher multiple, or as a distant event that doesn't change the near-term earnings story. The setup is clear: buy the news of the raised guide, but watch for any shift in sentiment around the Medical-Surgical separation.

Valuation and the Risk/Reward Check

The raised guidance narrows the range, providing more certainty, but the stock's valuation must now justify this elevated outlook. The tactical takeaway is clear: watch for confirmation of the IPO timeline and operational efficiency gains to support the new EPS guide. The event-driven play is to buy the news of the raised guide, but the risk is that the stock has already rallied on expectations.

The key near-term risks are execution on the Medical-Surgical IPO and any shift in prescription volume trends. The IPO target for the second half of 2027 is a multi-year process, but the timeline is critical for the stock's forward narrative. Any delay or uncertainty could dampen the premium investors might otherwise assign to the separation. At the same time, the core growth drivers-like GLP-1 distribution revenue reaching $14 billion, up 26% year over year-must hold. A stumble in prescription volumes or a slowdown in specialty distribution would directly pressure the new earnings targets.

The raised guide implies 17% to 19% growth for the year, a notable step-up. Management cited "stable utilization trends" and "operational efficiency initiatives" as supports, including a 138 basis point improvement in operating expenses as a percentage of gross profit. This efficiency gain is a tangible lever, but it must be sustained. The bottom line is that the event has changed the setup. The stock now trades on a higher multiple, priced for continued acceleration. The next catalyst is not another beat, but confirmation that the oncology platform expansion and the path to the Medical-Surgical IPO remain on track.